The Relationship Between Clotting Factor VIII and Bleeding Adverse Reactions in Patients Under the Therapies of Thrombolysis, Anticoagulation and Anti-platelet

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether Plasma Factor VIII Levels are related to the treatment of bleeding in ischemic stroke（IS）.

Detailed Description
-----------------
Clear cerebral infarction patients during hospitalization, treatment process, discharge and hemorrhage occurs, the stages F VIII level change and its correlation with bleeding adverse reactions. Analysis F VIII whether belong to hemorrhage occurs independent risk factors of adverse drug reactions,as well as the feasibility of predicting bleeding occurred adverse reaction index.

Conditions
-----------------
Bleeding, Ischemic Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Guidelines prepared by the diagnostic criteria(according to the diagnostic criteria of the Fourth National Stroke Conference prepared,have been more than one times skull CT and/or MRI)was confirmed for ischemic stroke,and requires the use of antithrombotic therapy(including thrombolysis, anticoagulation, antiplatelet) patients Willing and able to comply with the study protocol and visits planned Exclusion Criteria: At the same time the presence of other active malignancy. There is known brain metastases or leptomeningeal metastases Systemic active infection ( ie infection leads to body temperature ≥38 ℃) The last 4 weeks there is a need drainage ascites, pleural effusion or pericardial fluid . Clinically significant obstruction , pulmonary fibrosis , kidney failure , liver failure and other diseases. Uncontrolled diabetes. Severe / unstable angina, New York Heart Association (NYHA) class III or IV symptoms of congestive heart failure there is other reason (not the antithrombotic drugs) caused by bleeding. The presence of an autoimmune disease or a history of organ transplant patients require immunosuppressive therapy Psychiatric presence may increase the risks associated with study participation or study drug , or may interfere with the interpretation of study results Pregnant and lactating women Bleeding disorders may exist on admission The researchers added that the study is not appropriate to the circumstances

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| experimental group<br>The risk of bleeding adverse reactions when FVIII below the normal level. | |
| control group<br>The risk of bleeding adverse reactions when FVIII in normal level. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The levels of FVIII are measured by enzyme-linked immuno sorbent assay. |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Plasma Factor VIII Levels, Ischemic stroke, Antithrombotic therapy, Bleeding